Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.

Jiang L, Huang J, Higgs BW, Hu Z, Xiao Z, Yao X, Conley S, Zhong H, Liu Z, Brohawn P, Shen D, Wu S, Ge X, Jiang Y, Zhao Y, Lou Y, Morehouse C, Zhu W, Sebastian Y, Czapiga M, Oganesyan V, Fu H, Niu Y, Zhang W, Streicher K, Tice D, Zhao H, Zhu M, Xu L, Herbst R, Su X, Gu Y, Li S, Huang L, Gu J, Han B, Jallal B, Shen H, Yao Y.

PLoS Genet. 2016 Apr 19;12(4):e1005895. doi: 10.1371/journal.pgen.1005895. eCollection 2016 Apr.

2.

Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Miles RR, Shah RK, Frazer JK.

Br J Haematol. 2016 May;173(4):582-96. doi: 10.1111/bjh.14011. Epub 2016 Mar 11. Review. Erratum in: Br J Haematol. 2016 Nov;175(3):548.

3.

Notch signaling: its roles and therapeutic potential in hematological malignancies.

Gu Y, Masiero M, Banham AH.

Oncotarget. 2016 May 17;7(20):29804-23. doi: 10.18632/oncotarget.7772. Review.

4.

FBXW7 negatively regulates ENO1 expression and function in colorectal cancer.

Zhan P, Wang Y, Zhao S, Liu C, Wang Y, Wen M, Mao JH, Wei G, Zhang P.

Lab Invest. 2015 Sep;95(9):995-1004. doi: 10.1038/labinvest.2015.71. Epub 2015 Jun 22.

5.

Characterization of LEF1 High Expression and Novel Mutations in Adult Acute Lymphoblastic Leukemia.

Guo X, Zhang R, Liu J, Li M, Song C, Dovat S, Li J, Ge Z.

PLoS One. 2015 May 5;10(5):e0125429. doi: 10.1371/journal.pone.0125429. eCollection 2015.

6.

Diagnosis and subclassification of acute lymphoblastic leukemia.

Chiaretti S, Zini G, Bassan R.

Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014073. doi: 10.4084/MJHID.2014.073. eCollection 2014. Review.

7.

The challenge of targeting notch in hematologic malignancies.

Hernandez Tejada FN, Galvez Silva JR, Zweidler-McKay PA.

Front Pediatr. 2014 Jun 10;2:54. doi: 10.3389/fped.2014.00054. eCollection 2014. Review.

8.

From fly wings to targeted cancer therapies: a centennial for notch signaling.

Ntziachristos P, Lim JS, Sage J, Aifantis I.

Cancer Cell. 2014 Mar 17;25(3):318-34. doi: 10.1016/j.ccr.2014.02.018. Review.

9.

The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy.

Tosello V, Ferrando AA.

Ther Adv Hematol. 2013 Jun;4(3):199-210. doi: 10.1177/2040620712471368.

10.

NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia.

Bandapalli OR, Zimmermann M, Kox C, Stanulla M, Schrappe M, Ludwig WD, Koehler R, Muckenthaler MU, Kulozik AE.

Haematologica. 2013 Jun;98(6):928-36. doi: 10.3324/haematol.2012.073585. Epub 2013 Jan 24.

11.

The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.

Zuurbier L, Petricoin EF 3rd, Vuerhard MJ, Calvert V, Kooi C, Buijs-Gladdines JG, Smits WK, Sonneveld E, Veerman AJ, Kamps WA, Horstmann M, Pieters R, Meijerink JP.

Haematologica. 2012 Sep;97(9):1405-13. doi: 10.3324/haematol.2011.059030. Epub 2012 Apr 4.

13.

Impact of complex NOTCH1 mutations on survival in paediatric T-cell leukaemia.

Mansur MB, Hassan R, Barbosa TC, Splendore A, Jotta PY, Yunes JA, Wiemels JL, Pombo-de-Oliveira MS.

BMC Cancer. 2012 Jan 6;12:9. doi: 10.1186/1471-2407-12-9.

14.

Current views on the role of Notch signaling and the pathogenesis of human leukemia.

Pancewicz J, Nicot C.

BMC Cancer. 2011 Nov 30;11:502. doi: 10.1186/1471-2407-11-502. Review.

15.

Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D, Sangfelt O.

Breast Cancer Res. 2010;12(6):R105. doi: 10.1186/bcr2788. Epub 2010 Dec 1.

16.

Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies.

Aster JC, Blacklow SC, Pear WS.

J Pathol. 2011 Jan;223(2):262-73. doi: 10.1002/path.2789. Epub 2010 Oct 21. Review.

17.

Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.

Paganin M, Ferrando A.

Blood Rev. 2011 Mar;25(2):83-90. doi: 10.1016/j.blre.2010.09.004. Epub 2010 Oct 20. Review.

18.

T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation.

Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, Jette CA, Testa JR, Neuberg DS, Langenau DM, Kutok JL, Zon LI, Traver D, Fleming MD, Kanki JP, Look AT.

Cancer Cell. 2010 Oct 19;18(4):353-66. doi: 10.1016/j.ccr.2010.09.009.

19.

The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.

Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, Ludwig WD, Koehler R, Tolle G, Bandapalli OR, Breit S, Muckenthaler MU, Kulozik AE.

Leukemia. 2010 Dec;24(12):2005-13. doi: 10.1038/leu.2010.203. Epub 2010 Oct 14.

20.

Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223.

Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, Fatica A, Gorello P, Piciocchi A, Scappucci G, Bozzoni I, Fozza C, Candoni A, Guarini A, Foà R.

Haematologica. 2010 Jul;95(7):1114-21. doi: 10.3324/haematol.2009.015099. Epub 2010 Apr 23.

Supplemental Content

Support Center